Current and future testosterone delivery systems for treatment of the hypogonadal male

Bibliography

• Araujo AB, O'Donnel AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men; estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89(12):5920-6
   PubMed Web of Science ®Google Scholar
• Harman S, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001;86(2):724-31
   PubMed Web of Science ®Google Scholar
• Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med 2007;120:835-40
   PubMed Web of Science ®Google Scholar
• Neischlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004;10(5):409-19
   PubMed Web of Science ®Google Scholar
• Tenover JS. Declining testicular function in aging men. Int J Impot Res 2003;15(Supp4):S3-8
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002;5(3):170-5
   PubMedGoogle Scholar
• Lazarou S, Reyes-Vallejo L, Morgantaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med 2006;3(6):1085-9
   PubMed Web of Science ®Google Scholar
• Miller NL, Fulmer BR. Historical article: Injection, ligation and transplantation: the search for the glandular fountain of youth. J Urol 2007;177:2000-5
   PubMed Web of Science ®Google Scholar
• Edelstein D, Dobs A, Basaria S. Emerging drugs for hypogonadism. Expert Opin Emerging Drugs 2006;11(4):685-707
   PubMedGoogle Scholar
• Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84(10):3469-78
   PubMed Web of Science ®Google Scholar
• Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000;164(2):371-5
   PubMed Web of Science ®Google Scholar
• Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992;74(3):623-8
   PubMed Web of Science ®Google Scholar
• Wilson DE, Kaidbey K, Boike SC, Jorkasky DK. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998;20(2):299-306
   PubMed Web of Science ®Google Scholar
• Wang C, Berman N, Longstreth JA, et al.Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites. J Clin Endocrinol Metab 2000;85(3):964-9
   PubMed Web of Science ®Google Scholar
• Gooren LJG, Bunck MCM. Androgen replacement therapy; present and future. Drugs 2004;64(17):1861-91
   PubMed Web of Science ®Google Scholar
• Atkinson LE, Chang YL, Snyder PJ. Long term testosterone replacement through scrotal skin. In: Neischlag E, Behre HM, editors, Testosterone: action, deficiency, substitution. Berlin: Springer Verlag; 1998. p. 365-88
   Google Scholar
• Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim 1% testosterone gel in hypogonadal men. Rev Urol 2004;6(Suppl 6):S22-9
   PubMedGoogle Scholar
• Grober ED, Khera M, Soni SD, et al. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 2007;1-5
   PubMedGoogle Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2839-53
   PubMed Web of Science ®Google Scholar
• Rolf C, Knie U, Lemmnitz G, Nieschlag E. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol 2002;56(5):637-41
   PubMed Web of Science ®Google Scholar
• Carrasco D, Prieto M, Pallardo L, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate: review of the literature. J Hepatol 1985;1:573-8
   PubMed Web of Science ®Google Scholar
• Schubert M, Bullman C, Minnemann T, et al. Osteoporosis in male hypogonadism; responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 2003;60:21-8
   PubMed Web of Science ®Google Scholar
• Gooren LJ. A ten year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15(3):212-5
   PubMed Web of Science ®Google Scholar
• Skakkebaek NE, Bancrofs J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men; a double-blind controlled study. Clin Endocrinol 1981;14(1);49-61
   PubMed Web of Science ®Google Scholar
• Wittert GA, Chapman IM, Haren MT, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low–normal gonadal status. J Gerontol 2003;58A(7):618-25
   Google Scholar
• Kim S, Snipes W, Hodgen GD, Anderson F. Pharmacokinetics of a single dose of buccal testosterone. Contraception 1995;52(5):313-6
   PubMed Web of Science ®Google Scholar
• Dobs AS, Matsumoto AM, Wang C, Kipnes MS. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 2004;20(5):729-38
   PubMed Web of Science ®Google Scholar
• Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004;85(5):2039-43
   Google Scholar
• Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004;89(8):3821-9
   PubMed Web of Science ®Google Scholar
• Behre HM, Oettel AM, Hubler D, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism; Phase I studies. Eur J Endocrinol 1999;140:414-9
   PubMed Web of Science ®Google Scholar
• Schubert M, Minnemann T, Hubler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89(11):5429-34
   PubMed Web of Science ®Google Scholar
• Edelstein D, Sivanandy M, Shahani S, Basaria S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother 2007;8(17):2991-3004
   PubMed Web of Science ®Google Scholar
• Neischlag E, Buchter D, Von Eckardstein S, et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol 1999;51:757-63
   PubMed Web of Science ®Google Scholar
• Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005;6(10):1751-9
   PubMed Web of Science ®Google Scholar
• Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990;70:216-22
   Google Scholar
• Jockenhovel F, Vogel E, Kruetzer E, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol 1996;45:67-71
   Google Scholar
• Fabbri A, Isidori AM, Giannetta E, Lenzi A. Testosterone treatment to mimic hormone physiology in androgen replacement therapy; a view on testosterone gel and other preparations available. Expert Opin Biol Ther 2007;7(7):1093-106
   PubMed Web of Science ®Google Scholar
• De Lignieres B. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med 1993;25(3):235-41
   PubMed Web of Science ®Google Scholar
• Segal S, Narayanan R, Dalton JT. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Investig Drugs 2000;15(4):377-87
   Google Scholar
• Pantakar SS, Kaore SB, Sawane MV, et al. Effect of clomiphene citrate on sperm density in male partners of infertile couples. Indian J Physiol Pharmacol 2007;51(2):195-8
   PubMedGoogle Scholar
• Guay AT, Jacobson J, Perez JB, et al. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res 2003;15(3):156-65
   PubMed Web of Science ®Google Scholar
• Shabsigh A, Kang Y, Shabsign R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med 2005;2(5):716-21
   PubMed Web of Science ®Google Scholar
• Cummings DE, Kumar N, Bardin CW, et al. Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab 1998;83(12):4212-9
   PubMed Web of Science ®Google Scholar
• Venken K, Boonen S, Van Herck E, et al. Bone and muscle protective potential of the prostate-sparing synthetic androgen 7α-methyl-19-nortestosterone: evidence from the aged orchiectomized male rat model. Bone 2005;36(4):663-70
   PubMed Web of Science ®Google Scholar
• Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004;89(3):1174-80
   PubMed Web of Science ®Google Scholar
• Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002;167(2 Part 1):624-9
   PubMed Web of Science ®Google Scholar
• Johnsen SG. Maintenance of spermatogenesis induced by HMG treatment by means of continuous HCG treatment in hypogonadotrophic men. Acta Endocrinol 1978;89(4):763-9
   PubMedGoogle Scholar
• Liu P, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002;87(7):3125-35
   PubMed Web of Science ®Google Scholar
• Kabacki G, Yildirir A, Can I, et al. Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology 1999;92:221-5
   PubMed Web of Science ®Google Scholar
• English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21:890-4
   PubMed Web of Science ®Google Scholar
• Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995;74:693-7
   PubMed Web of Science ®Google Scholar
• Jones RD, Pugh PJ, Jones TH, Channer KS. Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminized mouse. Eur J Endocrinol 2003;148:111-20
   PubMed Web of Science ®Google Scholar
• Spark RF. Testosterone, diabetes mellitus, and the metabolic syndrome. Curr Urol Rep 2007;8(6):467-71
   PubMedGoogle Scholar
• Fukui M, Soh J, Tanaka M. Low serum testosterone concentration in middle-aged men with type 2 diabetes. Endocr J 2007;54(6):871-7
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14(3):226-34
   PubMedGoogle Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92
   PubMed Web of Science ®Google Scholar
• Viallard JF, Marit G, Mercie P, et al. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol 2000;110:237-8
   PubMed Web of Science ®Google Scholar
• Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med 2007;4:1241-6
   PubMed Web of Science ®Google Scholar
• Schneider BK, Pickett CK, Zwillich CW, et al. Influence of testosterone on breathing during sleep. J Appl Physiol 1986;61:618-23
   PubMed Web of Science ®Google Scholar
• Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab88(8):3605-13
   PubMed Web of Science ®Google Scholar
• Curran MJ, Bihrle W III. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999;53:423-4
   PubMed Web of Science ®Google Scholar
• Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol 1997;157:1845
   PubMed Web of Science ®Google Scholar
• Schatzl G, Madersbacher S, Thurridl T, et al. High grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47(1):52-8
   PubMed Web of Science ®Google Scholar
• Raivio T, Santti H, Schatzl G, et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003;55:194-8
   PubMed Web of Science ®Google Scholar
• Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14(9):2257-60
   PubMed Web of Science ®Google Scholar
• Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86(2):312-5
   PubMed Web of Science ®Google Scholar
• Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007;34:555-63
   PubMed Web of Science ®Google Scholar
• Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-6
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-2
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Clinical practice guideline: Testosterone therapy in adult men with androgen deficiency syndromes; an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006;91(6):1995-2010
   PubMed Web of Science ®Google Scholar